-
Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update
-
Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update
-
Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation
-
Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation
-
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma
-
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma
-
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024
-
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
